ABIVAX financials
Also U.S.-listed. ABIVAX is also a foreign private issuer filing with the U.S. SEC. View its EDGAR financials: ABVX — Abivax S.A.
ABIVAX
Country: FR Reporting currency: EUR Latest annual report: 2025-12-31
LEI:
969500D8TMNB184OJU95 Financial statements
(EUR, as reported — unscaled; 96 line items across 3 annual periods)
| Line item | 2025 | 2024 | 2023 |
|---|---|---|---|
| Income statement | |||
| Other income | €4.6M | €12.4M | €4.6M |
| Operating expenses | €250.6M | €185.4M | €132.0M |
| Operating profit (EBIT) | -€246.1M | -€173.0M | -€127.4M |
| Net finance income / (cost) | -€84.2M | -€3.3M | -€20.4M |
| Finance costs | €111.7M | €17.0M | €27.9M |
| Profit before tax | -€330.3M | -€176.2M | -€147.7M |
| Income tax expense | €5.8M | €0 | €0 |
| Profit for the year | -€336.1M | -€176.2M | -€147.7M |
| — attributable to owners | -€336.1M | -€176.2M | -€147.7M |
| Total comprehensive income | -€333.6M | -€176.5M | -€147.5M |
| Per share | |||
| Basic EPS | €-4.83 | €-2.80 | €-3.43 |
| Diluted EPS | €-4.83 | €-2.80 | €-3.43 |
| Free cash flow / share | €-2.32 | €-2.45 | €-2.26 |
| Cash flow statement | |||
| Net cash from operating activities | -€161.1M | -€154.1M | -€97.1M |
| Income taxes paid | €0 | €0 | €0 |
| Net cash from investing activities | -€8.2M | €15.8M | -€8.1M |
| Purchase of PP&E (capex) | €142.0K | €640.0K | €265.0K |
| Purchase of intangibles | €0 | €3.0K | €0 |
| Net cash from financing activities | €547.3M | €28.2M | €335.3M |
| Lease liability payments | €911.0K | €458.0K | €529.0K |
| Balance sheet | |||
| Total assets | €584.3M | €205.2M | €327.1M |
| Non-current assets | €33.1M | €34.6M | €41.1M |
| Intangible assets & goodwill | €18.4M | €18.4M | €18.4M |
| Current assets | €551.2M | €170.7M | €286.0M |
| Cash & equivalents | €516.7M | €144.2M | €251.9M |
| Total equity | €455.2M | €40.6M | €196.0M |
| — attributable to owners | €455.2M | €40.6M | €196.0M |
| Non-current liabilities | €66.1M | €70.6M | €40.4M |
| Current liabilities | €63.0M | €94.0M | €90.7M |
| Deferred tax liabilities | €5.8M | €0 | €0 |
| Derived metrics | |||
| Free cash flow | -€161.3M | -€154.7M | -€97.4M |
| Return on equity | -73.8% | -434.3% | -75.4% |
| Cash conversion ratio | 0.48× | 0.87× | 0.66× |
| Capex coverage | -1134.71× | -240.74× | -366.53× |
| Other reported items | |||
| Adjusted Weighted Average Shares | 69.5M | 63.0M | 43.1M |
| Adjustments For Decrease Increase In Trade and Other Receivables | €7.0M | €4.6M | -€14.2M |
| Adjustments For Depreciation and Amortisation Expense | €1.1M | €1.1M | €707.0K |
| Adjustments For Fair Value Gains Losses | €62.3M | €1.4M | -€1.2M |
| Adjustments For Income Tax Expense | €5.8M | €0 | €0 |
| Adjustments For Increase Decrease In Deferred Income Other Than Contract Liabilities | €710.0K | €1.8M | -€81.0K |
| Adjustments For Increase Decrease In Employee Benefit Liabilities | -€65.0K | €74.0K | €109.0K |
| Adjustments For Increase Decrease In Other Operating Payables | €2.1M | -€1.5M | €3.8M |
| Adjustments For Increase Decrease In Trade Account Payable | -€6.2M | -€3.4M | €31.8M |
| Adjustments For Interest Expense | €45.7M | €14.2M | €24.8M |
| Adjustments For Provisions | €44.7M | €0 | €0 |
| Adjustments For Sharebased Payments | €35.4M | €20.2M | €8.2M |
| Cash Flows From Used In Operations Before Changes In Working Capital | -€164.8M | -€155.5M | -€118.4M |
| Current Deferred Income Other Than Current Contract Liabilities | €0 | €0 | €52.0K |
| Current Derivative Financial Liabilities | €0 | €1.2M | €2.6M |
| Dividends Proposed Or Declared Before Financial Statements Authorised For Issue But Not Recognised As Distribution To Owners | €0 | €0 | €0 |
| Dividends Proposed Or Declared Before Financial Statements Authorised For Issue But Not Recognised As Distribution To Owners Per Share | €0.00 | — | — |
| Dividends Recognised As Distributions To Owners Per Share | €0.00 | €0.00 | €0.00 |
| Effect of Exchange Rate Changes On Cash and Cash Equivalents | -€10.3M | €2.4M | -€5.1M |
| Equity and Liabilities | €584.3M | €205.2M | €327.1M |
| Finance Income | €27.5M | €13.7M | €7.5M |
| General and Administrative Expense | €67.7M | €32.9M | €22.4M |
| Increase Decrease In Cash and Cash Equivalents | €372.5M | -€107.7M | €225.0M |
| Increase Decrease In Working Capital | -€3.7M | -€1.4M | -€21.3M |
| Increase Decrease Through Appropriation of Retained Earnings | €0 | €0 | €0 |
| Increase Decrease Through Sharebased Payment Transactions | €35.4M | €20.2M | €8.2M |
| Increase Decrease Through Treasury Share Transactions | — | €120.0K | €10.0K |
| Intangible Assets Other Than Goodwill | €6.6M | €6.6M | €6.6M |
| Interest Paid Classified As Financing Activities | €6.5M | €7.7M | €5.3M |
| Interest Received Classified As Investing Activities | €5.5M | €8.2M | €2.4M |
| Issued Capital | €785.0K | €633.0K | €629.0K |
| Noncurrent Derivative Financial Liabilities | €0 | €3.6M | €0 |
| Noncurrent Provisions For Employee Benefits | €627.0K | €756.0K | €629.0K |
| Number of Shares Issued | 78.5M | 63.3M | 62.9M |
| Other Adjustments For Noncash Items | €270.0K | €204.0K | €22.0K |
| Other Comprehensive Income | €2.5M | -€219.0K | €225.0K |
| Other Comprehensive Income Net of Tax Exchange Differences On Translation | €2.4M | -€187.0K | €112.0K |
| Other Comprehensive Income Net of Tax Gains Losses On Remeasurements of Defined Benefit Plans | €93.0K | -€31.0K | €112.0K |
| Other Comprehensive Income That Will Be Reclassified To Profit Or Loss Net of Tax | €2.4M | -€187.0K | €112.0K |
| Other Comprehensive Income That Will Not Be Reclassified To Profit Or Loss Net of Tax | €93.0K | -€31.0K | €112.0K |
| Other Current Financial Assets | €21.4M | €7.6M | €9.2M |
| Other Current Financial Liabilities | €0 | €0 | €3.5M |
| Other Inflows Outflows of Cash Classified As Financing Activities | €300.0K | €245.0K | €163.0K |
| Other Longterm Provisions | €28.8M | €819.0K | €30.0K |
| Other Noncurrent Financial Assets | €5.4M | €5.9M | €12.9M |
| Other Noncurrent Financial Liabilities | €0 | €0 | €3.3M |
| Other Noncurrent Nonfinancial Assets | €625.0K | €948.0K | €2.3M |
| Other Shortterm Provisions | €17.0M | €532.0K | €0 |
| Payments For Share Issue Costs | €40.9M | -€446.0K | €28.1M |
| Proceeds From Exercise of Warrants | €5.8M | €0 | €0 |
| Proceeds From Sale Or Issue of Treasury Shares | €0 | €434.0K | €10.0K |
| Property Plant and Equipment Including Rightofuse Assets | €2.1M | €2.7M | €878.0K |
| Research and Development Expense | €177.8M | €146.5M | €103.2M |
| Reserve of Exchange Differences On Translation | €2.3M | -€75.0K | €112.0K |
| Retained Earnings Excluding Profit Loss For Reporting Period | -€402.4M | -€262.6M | -€135.2M |
| Retained Earnings Profit Loss For Reporting Period | -€336.1M | -€176.2M | -€147.7M |
| Revenue and Operating Income | €4.6M | €12.4M | €4.6M |
| Sales and Marketing Expense | €5.2M | €6.0M | €6.4M |
| Share Issue Related Cost | €40.3M | -€446.0K | €28.1M |
| Share Premium | €1.19B | €478.9M | €478.2M |
| Trade and Other Current Payables To Trade Suppliers | €37.6M | €43.8M | €47.2M |
| Weighted Average Shares | 69.5M | 63.0M | 43.1M |
Methodology
Every line item above is a fact tagged in ABIVAX's annual report
filed in the European Single Electronic Format (ESEF) under the IFRS
taxonomy (ifrs-full) — the income statement, balance sheet
and cash-flow statement as the filer reported them. Values are shown
as-is, in the reporting currency (EUR), without
rescaling; the row labels map to the underlying concept name (e.g.
Revenue → ifrs-full:Revenue, Operating profit →
ifrs-full:ProfitLossFromOperatingActivities, Diluted EPS →
ifrs-full:DilutedEarningsLossPerShare), and any concept
without a curated label is shown under “Other reported items” with its
de-camel-cased tag name. Only consolidated, default-member facts are
shown (segment / dimensional breakdowns are excluded).
“Derived metrics” (free cash flow, margins, ROE, …) are computed from those facts by the same model the U.S. financials pages use — not tagged by the filer.
Source: machine-readable OIM xBRL-JSON aggregated by filings.xbrl.org (XBRL International). Entity identity is resolved by LEI via the public-domain GLEIF register. This is reference data, not investment advice.